The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

AIM: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targeting as an anti-cancer approach. BET degraders are chimeric compounds comprising of a BET inhibitor, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantelli, Chiara, Cannas, Eleonora, Ekeh, Hillarie, Moscatello, Carmelo, Gaudio, Eugenio, Cascione, Luciano, Napoli, Sara, Rech, Cesare, Testa, Andrea, Maniaci, Chiara, Rinaldi, Andrea, Zucca, Emanuele, Stathis, Anastasios, Ciulli, Alessio, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400774/
https://www.ncbi.nlm.nih.gov/pubmed/36046113
http://dx.doi.org/10.37349/etat.2021.00065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400774/
https://www.ncbi.nlm.nih.gov/pubmed/36046113
http://dx.doi.org/10.37349/etat.2021.00065

Ejemplares similares